MIST

Milestone Pharmaceuticals (MIST)

Milestone Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:MIST

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/22	21 : 00	GlobeNewswire Inc.	Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT Awareness	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2024/05/13	20 : 34	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2024/05/13	19 : 59	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2024/03/04	23 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2024/03/02	06 : 52	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2024/02/29	21 : 00	GlobeNewswire Inc.	Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2024/02/29	06 : 37	GlobeNewswire Inc.	Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2024/02/26	21 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2024/02/15	10 : 56	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2024/02/14	21 : 10	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/12/26	22 : 54	Dow Jones News	Milestone Pharmaceuticals Shares Sink 24% After Receiving Rejection from FDA	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/12/26	21 : 57	Dow Jones News	Milestone Pharmaceuticals' Etripamil Nasal Spray Application Gets FDA's Refusal to File Letter	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/12/26	21 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/11/21	21 : 00	PR Newswire (Canada)	Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/11/21	21 : 00	PR Newswire (US)	Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/11/13	21 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/11/13	20 : 57	PR Newswire (Canada)	Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/11/13	20 : 57	PR Newswire (US)	Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/11/13	20 : 37	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/11/13	20 : 09	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/11/12	00 : 00	PR Newswire (US)	Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/11/12	00 : 00	PR Newswire (Canada)	Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/11/10	06 : 43	Edgar (US Regulatory)	Form SC 13D - General statement of acquisition of beneficial ownership	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/11/07	23 : 07	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/11/07	21 : 00	PR Newswire (US)	Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/11/07	21 : 00	PR Newswire (Canada)	Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/10/25	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/10/24	20 : 00	PR Newswire (US)	Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/10/24	20 : 00	PR Newswire (Canada)	Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil	NASDAQ:MIST	Milestone Pharmaceuticals Inc
2023/10/06	20 : 00	PR Newswire (US)	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:MIST	Milestone Pharmaceuticals Inc